EGFR and glioblastoma: There have been several attempts to experimentally apply EGFR tyrosine kinase inhibitors, also inhibiting EGFRvIII, in glioblastoma therapy, as significant differences between kinase domains of mutated and wild-type receptor have not been described so far.